Where To Invest January 2016

Stock Market Investing Strategies

January 4, 2016

Market Strategies Newsletter

Sample Issue
Where To Invest January 2016

Balanced Investing Strategies To

Make Money In Up Or Down Markets


A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)

Contributing Staff: Michael King, Charles Moskowitz



Where To Invest In 2015 Newsletter Covering:


Where to Invest January 2016

Best Stocks To Buy January 2016

Stock Market Investing Strategies

Stock Options Trade Alerts

Options Trading Strategies

How To Trade Options


2015 YTD Profits $ 6646

Over 66% Returns



2014 Profits = $ 20,443

Over 204% Returns



NOTE: This is a Sample Issue Only!



Visit: PrincetonResearch.com/join.htm



For Free Where To Invest Your Money Now

High Return Investments Trade Alerts

Go To: PrincetonResearch.com/alerts.htm


$10,000 Trading Portfolio
Charles Moskowitz Discussion


We Have 1 Long Open Position:

CCOI  Jan 35 Calls


Funds  in Use  $ 510                           


We closed out the year with a gain of $6,646 and are carrying only one position of 6 CCOI 1/35 calls.  This uses $510 of our current funds which we roll back to $10,000 at the first of the year.


The last 4 days of the year were mixed and were actually looking pretty good for the Santa Claus rally.  Monday was quiet and we finished down, but at the high of the day.  Tuesday was up right out of the gate and was a great day.  The problems didn’t start in earnest until Thursday (Wed was an inside day) when we started seeing the pictures and reports about the Dubai fire.  It wasn’t the fact, but the possibility that it was going to turn out to be a terrorist action.  As it turned out, that seems  to not be the fact, but the issue remained and after a 170 point up reversal during the day in the DJIA, we fell back to close at the lows.  This means that unless we see two big up days for the first and second days of the new year, Santa has already come and gone…


Another issue that hasn’t really been discussed much on the Sunday morning shows is the Saudi executions including the killing of a major Shi’ite cleric.  While the Supreme leader is looking for “divine intervention I expect something a little more contemporary to occur.  This may put a new bid under the oil and maybe the gold.


This year has thrown an awful lot at the markets and frankly, closing slightly lower on the year doesn’t bother me at all.  The relative pessimism is good for the market.  The only area that has been a major problem is the transports.  We closed 2014 @ $9139 and this past year @ $7508, a decline of almost 18%.  While this has been damaging, it has not yet developed into the Dow Theory sell signal for the overall market.  The price of coal and oil (2 of the biggest cargo for the rails) has been so weak as to put most of the energy sector the biggest declines of the year.  However, I think that if oil was to simply stabilize the attitude would change.  If, as I also believe, that the problem with oil is one of supply, not demand, then the trucking, airline and railroads and chemicals will reap the advantage of cheaper fuel.


Another area that has had some problems after an extended period of monumental rise is Pharma.  The ETF for this group (XPH) had a low of $11.97 in early 2009 closed the year @ $51.20.  While the weekly chart looks like an unending rally from the lower left to the upper right this is deceiving because the weekly is smoothed by seeing it in the 6 year context including the 2:1 split in September of 2015.  In fact, there have been several retracements and corrections of 10-20%.  Just this past year we started with a high of $67.25 and even throwing out the “mini flash crash” low of $38 on 8/24, we had a real low of just over $43.  When you look at the long term chart on a daily or weekly basis this 36% decline looks like a normal pullback.  Right now we are oversold with stochastics at the low end of the range.  While the downside should be limited by support in the $49-50 area a move back to $60 wouldn’t surprise me at all…..CAM


Market Strategies $10,000 Trading Account Trade Table

New Trades

              ( 1  )  Buy  6 CNC Jan $   65  Puts $  1.10         Or Better

              ( 2  )  Buy 4  SPY Jan  $ 206 Puts @ $ 2.65


Sold 10 GLD January n104 Calls
      350 Loss
Bought 10 GLD January 104 Calls
Bought 6 CCOI January 35 Calls


Remember, these trades are based on your participation in the

Subscriber Members Only



Previous closed out trades not listed here may be seen in previous market letters in the

VIP Subscribers Members Area.



For Free Where To Invest Your Money Now

High Return Investments Trade Alerts

Go To: PrincetonResearch.com/alerts.htm



MARKET Laboratory – Weekly Changes


Prices are copied from Barron’s Weekly and Yahoo Finance and may be incorrect.









S&P 500








Russell 2000








Gold (spot)












Heating Oil




Unleaded Gas




Natural Gas








Put/Call Ratios

S&P 100



Put/Call Ratios

CBOE Equity





153-24 -1-10

3.02% +0.06%

10 Yr. Note

125-29 -084         2.27%+0.03%






CRB Inflation





Barron’s* Confidence







5 Yr. Note

118-102 -058

1.76% +0.05%






DJ Utilities








Long Term

















M1 Money  Supply


Dec 21st



M-2 Money



Dec 21st



* Component Change in the Confidence Index


M1…all money in hands of the public, Time Deposits Traveler’s Checks, Demand Deposits
M2.. adds Savings and Money Market Accounts both compared with the previous year.



Market Strategies Technical Information


                              Support/Resistance Levels:                SUPPORT                         RESISTANCE


S&P 500           2040 2019                          2068 2088

Dow                  17,160                                 17,683

QQQ             109.94                                  112.90

Transports        74.53                                    7787

NASDAQ           4970                                              5148


$100,000 Trading Portfolio Stock Positions and Trades


New Stock Recommendations:


1) Buy 800 KRO @ $ 5.75 Or Better


Each stock is allocated a theoretical $ 5,000 share of the portfolio unless otherwise indicated.  





Purchase Price Purchase Date Stop/Loss   Price/Date Sold   Profit/


EYES  1000 6.49       12/28      
RCII      300 15.55       12/28      
SLCA    300 18.56       12/23   18.97

stop close only

18.94 12/29 $ 114
ROK      100 99.58       12/21   102.14 12/22 $ 256
NFLX   -100 118.51 sold short         2/18   115.78 12/22 $ 273
APC      100 51.21       12/10      
VA         200 36.50       12/08      
APC      100 53.53       12/07      
LVLT    100 50.81       11/23      
TWTR  200 28.51       10/28      
SPXU  200 34.10       10/15      
CUBA   500   7.58       09/28      
MOS  100 43.55       08/14      
CRM  100 72.90       04/29      66.25    
NBGGY  600 1.40       02/17      
BAC. Wts 5,000 lots 0.7411       12/26      
BSBR  500






SAN  600 8.40      12/16      
AA  500 14.21      10/16      
NBGGY 300  2.95      05/19      
NBGGY 300 4.08 8/12      
TEXQY* 200 6.56 7/11      
REPR* 5000 0.22 10/22/12      


Remember, these trades are based on your participation in the

Subscriber Members Only



Previous closed out trades not listed here may be seen in previous market letters in the

VIP Subscribers Members Area.



For Free Where To Invest Your Money Now

High Return Investments Trade Alerts

Go To: PrincetonResearch.com/alerts.htm

For those of you who do not buy puts to protect your portfolio, there are many ETF’s that are the inverse of the DOW. The symbols are DOG, DXD, SDS,TZA and RWM, which go up when the  DOW, S&P 500 and Russell 2000 go down and down when they go up. The DZZ goes up double when gold goes down.




Market Strategies $100,000 Trading Account


             New Options Trades:


                       ( 1  )  Buy  12 CNC Jan $ 65    Puts $  1.10       Or Better

                       ( 2  )  Buy   8  SPY Jan $ 206  Puts @ $ 2.65



There was one closed option position:


The January 104 GLD Calls lost $ 700 being stopped out on the 50% loss rule.


The only open option  position is the 12 CCOI January $ 35 Calls which closed Friday at $ 0.50.

They were purchased at $ 0.85.


There was one closed out stock trade, the SLCA making $ 114.


New positions were established in both the EYES 1,000 and the RCII 300.


The total for the week was $ 586.


This reduced gains for the year to $13,216.


The options expire on the third Friday of each Month unless otherwise posted.


The Stock table has the following 20 positions:





The options call for a $ 2,500 investment unless otherwise stated; each stock position requires $5,000 unless otherwise mentioned specifically.


We are basing money management on a hypothetical

$ 100,000 and are using a total of

$   87,474 for the 20 open stock positions.


There is one long option position requiring

$   1,020.which added to the stock longs totals an outlay of $ 88,494.00 leaving

$ 11,506 in cash.


These figures are approximate and there might be errors.


We have not counted the dividends received from Apple, JP Morgan, North American Tankers, Santander, their Brazil affiliate BSBR and Blue Capital Reinsurance which was sold for a profit and many others. We will begin adding them next year.


Executions that have occurred at or near the open or close of trading sometimes vary from our actual numbers.  For example, when something opens down and it is through our price, we take the next trade whether it is an uptick or continues lower.  This sometimes results in a 50% trade that is slightly above or below the exact number.



Previous Week’s Recommendations and

Rules for the Market Strategies

$100,000 Portfolio Trading Account

  • All options count for about $ 2,500.00 for model portfolio calculations unless

otherwise stated


  • When the option has doubled sell half the position


  • Stop Loss protection is either half or offered with each trade


  • The cost of the option is the asking price (or the price between the bid and ask,

whichever is more realistic)


  • The options will be followed until closed out.


  • Option Symbols are stock symbol with expiration month and strike price


Option Cost Date Sold Date Profit/


GLD Jan 104

20 lots



12/28/15 0.34 12/30/2015 ( $ 700 )
CCOI Jan 35

12 lots





Remember, these trades are based on your participation in the

Subscriber Members Only



Previous closed out trades not listed here may be seen in previous market letters in the

VIP Subscribers Members Area.



For Free Where To Invest Your Money Now

High Return Investments Trade Alerts

Go To: PrincetonResearch.com/alerts.htm



This Weeks’ Economic Numbers

Earnings Releases and Media Data

Before the Open on top of the Row;

After the close below the Economics Information


MONDAY 10:00 hrs Construction Spending Nov ( 0.8% vs 1.0% )

10:00 hrs ISM Services Dec ( 49.0 vs 48.6 )

The American Economic Association holds its annual meeting in San Francisco with John Williams, president of the San Francisco Fed scheduled to participate

TUESDAY Commercial Metals CMC  ( 0.25 vs 0.32 )

14:00 hrs Auto Sales Dec   ( NA  vs +5.7 Mln )

14:00 hrs Truck Sales Dec ( NA vs 8.7 Mln )

Goldman Sachs forecasts that 18.3 million light vehicles were sold, versus 18.2 million the previous month and that 6.2 million domestic cars were sold up from 5.7 million in Nivember.

Landec LNDC ( 0.06 vs 0.12 ) Sonic SONC ( 0.23 vs 0.18 )Team TISI 0.84 vs 0.80



WEDNESDAY Monsanto MON ( -0.27 vs 0.47 ) MSC Industrial MSM ( 0.87 vs 0.95 ) RPM Inc

RPM ( 0.57 vs 0.52 ) UniFirst UNF ( 1.65 vs 1.85 )

07:00 hrs MBA Mortgage Index  01/02   ( NA vs +7.3% )

07:15 hrs ADP Employment Change  December  ( 190K vs 217K )

08:30 hrs Trade Balance November  ( -$44.7Bln vs -$43.9Bln )

10:00 hrs Factory Orders November ( -0.2% vs + 1.5% )

10:30 hrs Crude Inventories 01/02 ( NA vs +2.629 Mln Bbls )

FOMC Minutes could give hints about future policy and provide more detail behind the decision last month to increase short term interest rates for the first time in nearly a decade.

Mistras Group MS ( 0.26 vs 0.33 ) Nobilis Health HLTH ( 0.04 ) RECN  0.24 vs 0.22



THURSDAY Constellation Brands STZ ( 1.29 vs 1.23 ) Walgreens Boot Alliance WBA ( 0.97 )

Schnitzer Steel  SCHN ( -0.15 vs 0.08 ) KB Home KBH ( 0.51 vs 0.27 )

07:30 hrs Challenger Job Cuts Dec ( NA vs -39.0% )

08:30 hrs Initial Claims 01/02  ( NA  vs 287K )

08:30 hrs Continuing Claims 12/26 ( NA  vs 2198K )

10:30 hrs Natural Gas Inventories Dec ( NA vs -58bcf )

Bed Bath & Beyond BBBY ( 1.09 vs 1.19 ) Synnex SNX (  1.76 vs 1.83 ) Helen of Troy HELE ( 1.91 vs 2.17 ) PriceSmart PSMT ( 0.83 vs 0.68 ) Franklin Covey Company FC ( 0.03 vs 0.11 ) Ruby Tuesday RT ( -0.08 vs -0.15 ) WD-40 WDFC

( 0.80 vs 0.73 ) AngioDynamics ANGO ( 0.14 vs 0.17 ) Barracuda CUDA ( 08 vs 06)


FRIDAY Acuity Brands AYI ( 1.58 vs 1.32 ) AZZ ( 0.89 vs 0.75 ) Synergy 01 vs 0.26

08:30 hrs Nonfarm Payrolls Dec  ( 200K vs 211K )

08:30 hrs Nonfarm Private Payrolls Dec ( 194K vs 197K )

08:30 hrs Unemployment Rate Dec ( 5.0% vs 5.0% )

08:30 hrs Hourly Earnings Dec ( 0.2% vs 0.2% )

08:30 hrs Average Workweek Dec ( 34.5 vs 34.5 )

10:00 hrs Wholesale Inventories Nov ( -0.1% vs -0.1% )

15:00 hrs Consumer Credit Nov ( $ 18.5B vs $ 16.0B )




    Market Strategies Fundamentals

          Scoreboard for 2015

Index 12/31/15 close


As you can see from the table on the left, Nasdaq stocks were higher, as most of the glamour stocks led by Apple, Amazon, Netflix, Facebook, and Alphabet (formerly Google) make up this index, which they completely dominated.

Consumer Discretionary SPDRS were the best up 26.7%, while the Energy Spider was the worst off 23.7%.


The S&P 500 was practically unchanged yet 60% of these stocks are below their 200-day moving average. The large majority of the S&P 500 index and Dow were lower even though their Spiders were mostly higher. The higher cap stocks making the vast majority of the Spiders outperformed lower capitalized shares.


Change %

 DJI 17425.03 -2.2


5007.41 +5.7
S&P 500 2043.94 -0.7
Stoxx 600 365.81 -4.1
Nikkei 19033.71 -0.4


3539.18 -4.4
WTI Crude

Oil barrel

37.04 -30.5
US Dollar


98.65 +9.3



2.27% +0.1



373.69 -14.6


The A/D line is a cumulative breadth indicator. It has been negative all year not responding when major indexes such as the Dow or S&P 500 made new all- time highs. A large amount of S&P 500 stocks have been in a bear market ( considered down 20% or more )

The year had a very mixed picture with Consumers benefitting from lower costs: A strong greenback lowered retail prices, while lower gasoline prices provided extra spending dollars. As mentioned in the chart above, Consumer Discretionary ( XLY : $ 78.16 ) + 16.48 or 26.7% had by far the best gain. The Consumer Staples Spider ( XLP: $ 50.49 ) + 6.80  improved by 15.6% for the year; Health Care ( XLV $ 72.03 ) + 3.65 or 5.1% was third best. The Technology Spider ( XLK: $ 42.83 ) + 1.48 or 3.6% was slightly higher. The S&P 500 Industrial Spider was lower for the year ( XLI: $ 52.77 ) – 3.81 or -6.7%. Getting hurt much worse of course were both the Materials and Energy Spiders:. The Energy Spider was the worst performer ( XLE: $ 60.32 ) – 18.84 or 23.8%. The S&P  Materials Spider  ( XLB: $ 43.42 ) -5.16 was off 11.9%.

The Dow lost 0.72% or 127 points for the week to close at 17,425.03 down 2.2% for the year. The best performing Dow stock was NIKE ( NKE: $ 62.50 ) + $ 20.58 up 49% for the year. The worst performance was for Wal-Mart Stores ( WMT: $ 61.30 ) down $ 24.58 or 28.6%.






Market Strategies Economic Data

The Conference Board’s Consumer Confidence Survey increased to 96.5 in December (Briefing.com consensus 93.5), up from 92.6 in November and from 93.1 in December 2014.The December survey marked the first increase in consumer confidence since September.

The improvement in December stemmed from a pickup in both the Present Situation Index (from 110.9 to 115.3) and the Expectations Index (from 80.4 to 83.9).

According to The Conference Board, consumers remain positive about the current state of the economy and particularly the job market. They aren’t expecting much change in business conditions and the labor market in 2016, yet it was noted that optimists continue to outweigh the pessimists.

Confidence surveys don’t have a strong correlation with actual consumer spending activity, which is tied more strongly to income growth. On that note, the survey showed the proportion of consumers expecting their incomes to increase slipped to 16.3 percent from 17.3 percent while the proportion expecting a reduction in income also decreased to 9.7 percent from 11.8 percent.

Conference Board 96.5 92.6 99.1 102.6 101.3
  Expectations 83.9 80.4 88.7 90.8 91.6
  Present Situation 115.3 110.9 114.6 120.3 115.8
Employment (‘plentiful’ less ‘hard to get’) -0.6 -4.8 -1.9 -0.1 0.4
1 yr inflation expectations 4.8% 5.0% 5.1% 5.1% 4.9%



Market Strategies Cycles


If Santa should fail to call the bears may come to Broad and Wall.


The Santa Claus pattern has been negative so far with four of the first five days going lower. December 29th, the second day of the cycle, was positive by 21.86; the other four were negative: The first day of the pattern, the 28th was a negative 4.40; the 30th the third day was a negative 15 while the 31st was a big down day off 19.42. The four down days total 42.13 points while 21.86 was the total gain for a negative net of 21.27 with two days remaining.


Against a global background of collapsing commodities and a soaring US$, the US economy continues to be buoyed up by full employment, plenty of jobs with rising wages and  US consumers, who continue to buy houses, cars, and decent general retail spending. The weakness in the industrial sector might cause a negative first quarter. Notwithstanding all the negativity, it is an election year which is bullish. In addition, the consumer/ service sector remains strong enough to counter balance industrial weakness and cause support for the general economy.

The strength in the U.S. dollar will almost certainly be a background issue yet less threatening than it was in 2015. Asia should recover with strength coming from China, Vietnam, Korea and Indonesia. Emerging nations like Brazil, and Venezuela  will continue to have difficulties while Argentina will continue to improve.

Health Care has been one of the leading S&P Spiders ( XLV: $72.03 ) up 5.80 or 8.8% since September 30th.That index remains attractive and Akom ( AKRX: $ 37.31 )  is a member. It has a short interest of 13.2% of the float;  weekly high April 24th at $57.10; weekly low October 22nd at $19.08 , 50 day moving average at $ 34.36. 200 day moving average is at $ 37.12.Akom has had a nice rally into the end of last year. We would consider buying this somewhere, perhaps at its 50 day moving average towards the $ 34 level. More aggressive traders might look at the 13-day M.A. at $ 35.90.



Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products in the United States and internationally.


It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment markets generic and branded ophthalmics,  injectables, oral liquids, optics, topical, inhalants, and nasal sprays. This segment’s generic products include Clobetasol Propionate, a corticosteroid, which is used to treat various skin conditions; Fluticasone Propionate, a corticosteroid used for nasal symptoms of allergic and non-allergic rhinitis conditions; Lidocaine/Prilocaine, a topical anesthetic; Progesterone, which is used to prevent endometrial hyperplasia; Vancomycin, an antibiotic used to treat bacterial infections; and other products.


The Consumer Health segment markets branded and private label animal health products, as well as OTC products for the treatment of dry eye under the TheraTears brand name. This segment’s branded products comprise Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; Nembutal, a sedative; and Xopenex inhalation solution for the treatment or prevention of bronchospasm. It also markets other OTC consumer health products, including Mag-Ox, a diabetes magnesium supplement, and the Zostrix brand of capsaicin products for pain management; and animal health branded and generic products comprising Anased, Tolazine, Yobine, Butorphic, and VetaKet. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.



AT&T (NYSE:T $ 34.46 ) is an excellent investment. Their acquisition of Direct TV puts them in competition with Net Flix.  The dividend will continue to be raised be and more than a penny. With the DirecTV purchase, there are strong sources of revenues, but the company has been saddled with debt. By paying this down, while upping its payout, the stock is incredibly attractive. The prospects for growth and appreciation are excellent.




The Hirsch legendary cycle work was begun by Yale Hirsch and now continued by his son Jeff.


January has quite a legendary reputation on Wall Street as an influx of cash from yearend bonuses and annual allocations typically propels stocks higher. January ranks #1 for NASDAQ (since 1971), but fifth on the S&P 500 and sixth for DJIA since 1950. January is the end of the best three-month span and possesses a full docket of seasonal indicators.


This year, the best three months were all positive with the lone exception of the DJ Transportation Index. The Nasdaq was the best during this bullish cycle period, up 9.3% followed by the Dow up 7.8%. The S&P rose 7.3% and even the Russell was up .9%. The Tranny was off 2.1%.


The first indicator to register a reading in January is the Santa Claus Rally. The seven-trading day period begins on the open on December 24 and ends with the close of trading on January 5. Normally, the S&P 500 posts an average gain of 1.5%. The failure of stocks to rally during this time tends to precede bear markets or times when stocks could be purchased at lower prices later in the year.


DJIA and S&P rankings did slip from 2000 to 2015 as both indices suffered losses in nine of those sixteen Januarys with three in a row, 2008, 2009 and 2010. January 2009 has the dubious honor of being the worst January on record for DJIA (-8.8%) and S&P 500 (-8.6%) since 1901 and 1931 respectively. After three straight gains from 2011 to 2013, S&P 500 was off 3.6% in 2014 and 3.1% in 2015.


Pages 106 and 110 of the Stock Trader’s Almanac 2016  illustrates that the January Effect, where small caps begin to outperform large caps, actually starts in mid-December. Early signs of the January Effect have yet to materialize this year as iShares Russell 2000 (IWM) continues to lag behind SPDR S&P 500 (SPY). The majority of small-cap outperformance is normally done by mid-February, but strength can last until mid-May when most indices reach a seasonal high.


On January 8, the Stock Trader’s Almanac First Five Days “Early Warning” System will be in. In presidential election years this indicator has a solid record. In the last 16 presidential election years 14 full years followed the direction of the First Five Days. The full-month January Barometer has a presidential-election-year record of 12 of the last 16 full years following January’s direction.



January (1950-2015)
  DJI SP500 NASDAQ Russell 1K Russell 2K
Rank 6 5 1 6 3
# Up 42 40 29 23 20
# Down 24 26 16 14 17
Average % 1.0   1.0   2.7   1.0   1.7
4-Year Presidential Election Cycle Performance by %
Post-Election 0.7   0.7   2.2   1.6   2.0
Mid-Term -0.9 -1.0 -0.7 -1.3 -0.9
Pre-Election 3.7 3.9 6.6 2.9 3.2
Election 0.3 0.5 2.6 0.7 2.3
Best & Worst January by %
Best 1976 14.4 1987 13.2 1975 16.6 1987 12.7 1985 13.1
Worst 2009 -8.8 2009 -8.6 2008 -9.9 2009 -8.3 2009 -11.2
January Weeks by %
Best 1/9/76 6.1 1/2/09 6.8 1/12/01 9.1 1/2/2009 6.8 1/9/87 7.0
Worst 1/24/03 -5.3 1/28/00 -5.6 1/28/00 -8.2 1/28/00 -5.5 1/4/08 -6.5
January Days by %
Best 1/17/91 4.6 1/3/01 5.0 1/3/01 14.2 1/3/01 5.3 1/21/09 5.3
Worst 1/8/88 -6.9 1/8/88 -6.8 1/2/01 -7.2 1/8/88 -6.1 1/20/09 -7.0
First Trading Day of Expiration Week: 1990-2015
#Up-#Down   16-10   12-14   12-14   11-15   11-15
Streak   D2   D3   D3   D3   D3
Avg %   -0.02   -0.05   0.001   -0.1   -0.03
Options Expiration Day: 1990-2015
#Up-#Down   15-11   14-12   13-13   14-12   14-12
Streak   U5   U1   U1   U1   U1
Avg %   -0.1   -0.1   -0.2   -0.1   -0.1
Options Expiration Week: 1990-2015
#Up-#Down   13-13   9-17   14-12   9-17   13-13
Streak   D1   D2   D1   D2   D1
Avg %   -0.3   -0.3   -0.1   -0.3   -0.1
Week After Options Expiration: 1990-2015
#Up-#Down   12-14   15-11   13-13   15-11   18-8
Streak   U1   U1   U1   U1   u1
Avg %   -0.5   -0.3   -0.1   -0.2   0.06
January 2016 Bullish Days: Data 1995-2015
  4, 5, 25 19, 27 4, 11, 12, 19 11, 12, 19 8, 11, 19, 26
      20, 26, 27 26, 27 27, 29
January 2016 Bearish Days: Data 1995-2015
  8, 21, 22 21 21, 22 21 21


Undervalued Small Cap Stocks

Lower Priced stocks that look to be a buy:


Repro-Med Systems, Inc ( OTCQX:  REPR 0.55 )* 


Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) announced that its net revenues for the third quarter ended November 30 for fiscal 2016 increased 18% over the previous year’s Q3, led by the Company’s sales of proprietary infusion products. The Company’s current fiscal year ends February 28, 2016.

Revenues for the third quarter of fiscal 2016 were $3,145,000 compared with $2,655,000 for the third quarter of fiscal 2015. Revenues for the first nine months of the fiscal 2016 were $8,942,000 compared with $7,797,000 for the same period last year, an increase of 15%.

RMS continues to benefit from recent lean manufacturing initiatives, which have resulted in increased capacity and decreased direct assembly labor costs compared to last year. Gross margin improved in fiscal Q3 to 67% from 60% in the same quarter last year, and from 63% in fiscal Q2.

Driven by the strong sales in the quarter, net income for the third quarter was $168,000, an improvement of 81% compared with the same period last year. In addition, net income was negatively impacted due to costs associated with several trade shows in the quarter, the hiring of new sales representatives, and continued legal and consulting fees, all of which reflect an investment for growth in future periods. Excluding certain of these non-recurring items, net income margin would have been in excess of 10% for the quarter.

“We continue to see growth in all sectors of the homecare infusion market both domestically and internationally,” commented Andy Sealfon, President and CEO of the company. “I am also very excited about our newest board member, Cyril N. Narishkin and have appointed him as Interim Chief Operating Office to support our expanded management team and accelerate our growth opportunities. Cyril brings a wealth of experience consulting with companies of all sizes, and will also be instrumental in assisting the Company on its lean initiatives and growth plans,” Mr. Sealfon added.

The Company manufactures medical products used for infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60(R) and our latest FreedomEdge(TM) Syringe Infusion Pumps, RMS Precision Flow Rate Tubing(TM) and RMS HIgH-Flo(TM) Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The company’s RES-Q-VAC line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers.

The Company’s website may be visited at www.rmsmedicalproducts.com.

Repro-Med Systems, Inc has had an increase in sales each of the last four years. They finished the year of 2014 with $ 11.2 million in sales reflecting top line growth of  29% from 2013.In each of the previous two years they had a 12% increase in sales. The company has had at least $ 700 thousand of net income in each of the past four years and has no debt. The patented needle sets alone can give the company a huge growth potential. In my opinion, with new products coming on stream, the stock should trade between $ 3 and $ 8 in the next two years.


ProtoKinetix, Incorporated ( PKTX: 0.07 8

ProtoKinetix (www.protokinetix.com) trading at $ 0.0521 low and 0.0969 high on Friday has a huge upside potential. They are in collaboration with the James Shapiro laboratory at the University of Alberta. The sole intention of the collaboration is to develop a commercial product pipeline of therapeutic applications for the AAGP™ family of molecules.

Professor James Shapiro is Professor of Surgery, Medicine and Surgical Oncology, and Director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Program at the University of Alberta in Edmonton, Canada. He has a busy hepatobiliary surgical practice in HPB oncology, and in liver and kidney-pancreas transplant surgery. His center carries out 80 liver transplants per year, and has done around 80 living donor liver transplants. The University of Alberta just celebrated their 1000th liver transplant.

Dr. Shapiro directs the largest clinical islet transplant program worldwide with almost 170 patients treated, and led the clinical team that developed the “Edmonton Protocol” – the first trial to achieve consistent 100% insulin independence in a series of islet-alone transplant recipients with Type 1 diabetes (published in the NEJM 2000). Before Dr. Shapiro’s trial, the success rate with islet transplantation was less than 8%. He led an international multicenter trial to replicate these findings in 9 international centers (published in NEJM 2006).

Over the last 32 months Dr. Shapiro and his team have been extensively testing the AAGP™ molecule in allogeneic transplants using  human islet cells as the model. As regenerative medicine is rapidly becoming adopted in the treatment of degenerative diseases, the protection of the transplanted cells, tissues, and organs is of paramount importance. Transplanted cells and tissues are subjected to extreme stress factors that, unless protected, could cause failure to graft or premature death. The success of the tests  conducted in Edmonton have demonstrated that AAGP™ has the potential to be widely adopted in many areas of regenerative medicine.


Immune Therapeutics ( OTCQB: IMUN  $ 0.24 )

Appears ready to go; up 20% on the week. This biotechnology company is seeking to commercialize patented therapies in emerging nations that combat chronic, life-threatening diseases by rebalancing the immune system. The trials in Africa are going well.

The value of Naltrexone as an immune modulator was recognized by Dr. Ian Zagon at the University of Pennsylvania.2,3 The late Dr. Bernard Bihari, a Neurophysician from New York, USA (who passed away on May 16th, 2010) began treating his patients in the late 1980s4,5. Since that time, many doctors throughout the United States prescribe LDN for a number of indications including Multiple Sclerosis (MS), Parkinson’s disease, Crohn’s disease, HIV/AIDS, cancer and other autoimmune and inflammatory diseases.  A number of research and clinical trials have been completed and undergone in regards to LDN immunotherapies, with phase I and phase II clinical trials successfully run at a number of universities in the United States and Europe, including Pennsylvania State University Medical School at Hershey; University of Chicago; State University of New York; SUNY Upstate Medical University; London Health Sciences Centre – University Hospital, USA; Alpert Medical School of Brown University; Department of Neurology, San Raffaele Scientific Institute; Division of Rheumatology, St. Louis College of Pharmacy; Department of Internal Medicine, University of Utah; Jondi-Shapoor University of Medical Sciences; Department of Psychiatry & Behavioral Sciences, Duke University Medical Center; and Multiple Sclerosis Center at UCSF6. These efforts were pioneered by leading immunologists Dr. Nicholas Plotnikoff, Dr. Ronald Herberman, Dr. Bernard Bihari, Dr. Angus Dalgleish, Dr. Ian S. Zagon, Dr. Jill Smith, Dr. McLaughlin, Dr. Jacqueline McCandless, and Moshe Rogosnitzky, among others.


iSign Media Solutions  ( ISDSF: $ 0.11 ) ISD in Canada (0.17-0.18 ).


The beauty of buying the stock in the USA — You get a discount of 0ver 20% because the dollar is much stronger than the Canadian dollar.

iSIGN Media Solutions Inc is public company trading on the Toronto Stock Exchange Venture market under the symbol ISD (TSX-V: ISD), and in the United States  under the symbol of ISDSF. iSIGN became a public entity in September 2009.

iSIGN is a Software as a Service (“SaaS”) company whose US patented software (patent # 8,781,887 B2, received in July 2014) is a unique ‘push and pull’ technology that utilizes Bluetooth and Wi-Fi to ‘push’ messages in any language to mobile devices within a 300 ft (100 meter) radius of our technology, while gathering valuable information from the interaction of our technology with mobile devices within range of our hardware.

Customer Targeting

The technology and products can be employed across multiple channels from general retail outlets to real estate. Essentially, our technology and products can be utilized wherever a seller wishes to interact with shoppers in proximity to their location. Our initial customer targeting is convenience stores and gas stations, as this is a fast growing channel, that has over 150,000 locations, with approximately 126,600 linked to gas stations in the US, generating in excess of $700 billion in annual revenue. The problem faced by C-store/gas stations, is that 37% of their customers pay at the pump and don’t step foot within the store. Margins at the pump are 5.1%, while store margins are 22.4%. The average inside sale is only $4.85. All quoted figures taken from the 2013 NACS Annual Report. These problems can easily be addressed and mitigated by using our products.


Fundamental Analysis Stocks To Buy with Stops


We are long the Alcoa with a stop at 8.87. Dycom we are looking for a place to buy.


LUV and  VA were stopped out  with very nice gains. .


We want to be a buyer of both once again,. Both  Intel and Kroger are excellent positions. Hold.


Enzo Biochem ( ENZ ) remains cheap. Hold.


Continue to buy Bank of America on dips. We have not been able to get filled on theoretical orders to buy Microsoft .  Deere was filled and stopped out . We bought again on a dip. Date below price indicates the activity.



Symbol Name Business Description PE P/S MV mln Price Buy Limit Stop Loss

Or sold

AKRX Akorn, Inc Drug Manufacturing 100 7.15 4.3B 37.31 34.60 33
T AT&T Communications 36 1.54 211.7B 34.46 34.40 32x
AA Alcoa Alumina Aluminum products and innovations 24 0.51 12.24B 9.87 9.33 8.87
DY Dycom Industries Internet Cable Provider 28 1.10 2.5B 69.96 66.60

Price to buy

MSFT Microsoft Technology Software, Services, Devices 17 4.7 431B 55.48 53


DE Deere Farm and Construction equipment 13 0.84 26.3B 76.27 77.15


KR Kroger Food Mfg and Processing 18 0.33 37B 41.83 36.76


INTC Intel Technology chips platforms processors 13.6 2.8 152.83B 34.98 30.48


VA Virgin Air Regional Airlines 7.2 1.0 1.5B 36.33 36

Suggested buy

LUV Southwest Air Regional Airlines 16 1.15 22.6B 43.90 40.41




ENZ Enzo Biochem Life Sciences NA 1.35 134M  4.69 2.78


BAC Bank of America Commercial Bank 10 2.02 165.3B 17.27 17.05 16.92x stopped out
HDGE Advisor Shares Ranger Bear ETF       10.76 Buy 10.68 10.55X


NOTE: This is a Sample Issue Only!



Visit: PrincetonResearch.com/join.htm



For Free Where To Invest Your Money Now

High Return Investments Trade Alerts

Go To: PrincetonResearch.com/alerts.htm



Rule 17B Attestations and Disclaimers


Princeton Research, Inc. has approximately 2,581,578 shares of AIVN both free and restricted and represents them for Investor relations. Princeton also has about 40,000 shares of TXGE. Princeton is paid $ 1,500 per month from RMS Medical Products. Princeton has bought 81,100 shares of RMS Medical Products. Princeton was paid $ 2,500 to write a report on Xinergy. Princeton has signed a contract with CBLI to be paid $ 2500 for July and August for investor relations. Princeton has been engaged by Target Energy. No contract is currently in place. Princeton was paid about 500,000 restricted shares of Leo Motors.


When there is no movement in penny stocks, even though there is none or very small losses, we will liquidate ( sold AIVN on stop ) even though we like the company, if money is needed for better opportunities.


We now believe REPR represents upside opportunity. The Target ADR trades at about $ 4.50 in U.S. vs 0.05 in Australia. Princeton owns 400,000 Australia shares and about 900 U.S. ADR’s.


Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this e-mail issue. Princeton may buy or sell its free-trading shares in companies it represents at any time.




Please Direct All Inquiries To:


Mike King

(702) 650-3000



Charles Moskowitz

 (781) 826-8882



Princeton Research

3887 Pacific Street,

Las Vegas, Nevada 89121